Literature DB >> 2081723

Decontamination of the bowel by intravenous administration of pefloxacin.

E J Vollaard1, H A Clasener, A J Janssen.   

Abstract

Intravenous administration of pefloxacin 400 mg twice daily rapidly decontaminated the bowel from Gram-negative bacilli in ten healthy volunteers. The faecal concentrations of enterococci and yeasts did not change significantly. Further, pefloxacin did not facilitate colonization of the bowel by a highly resistant challenge strain (Klebsiella pneumoniae, MIC = 56 mg/l). The diffusible faecal concentration of pefloxacin was between 110 and 260 mg/l in all samples from day 3 of treatment onwards. It is concluded that parenteral administration of pefloxacin is very effective for decontamination of the bowel from Gram-negative bacilli and provides reliable prophylaxis against colonization of the bowel by highly resistant Gram-negative bacilli ingested with food.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081723     DOI: 10.1093/jac/26.6.847

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Influence of pefloxacin on microbial colonization resistance in healthy volunteers.

Authors:  E J Vollaard; H A Clasener; A J Janssen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

Review 2.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

3.  Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients.

Authors:  J J van de Leur; E J Vollaard; A J Janssen; A S Dofferhoff
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

4.  Enoxacin ameliorates polycystic ovary syndrome by promoting the browning of white adipose tissue and restoring gut dysbiosis.

Authors:  Wanlong Zhu; Liya Fu; Changjing Xu; Ke Peng; Yuanzhi Liu; Hui Tang; Yilan Huang; Xuping Yang
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 5.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.